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timulation and IL-4, IL-2, and rapamycin. Differential in gene
expression proﬁle was conﬁrmed during trial implementa-
tion (n¼39 T-Rapa12 and T-Rapa6 products evaluated). As in
the initial trial, T-Rapa6 cells were infused at d14 post-HCT
(2.5 x 107 cells/kg). Patients (pts; n¼44) received outpatient
chemotherapy (until CD4 < 200 cells/ml) and then received
an HLA-matched sibling mobilized allograft. GVHD prophy-
laxis was cyclosporine plus short-course sirolimus (to d14
post-HCT); low-intensity conditioning was ﬂudarabine (120
mg/m2) and cyclophosphamide (1200 mg/m2). Relative to T-
Rapa12 pts, T-Rapa6 pts had similar characteristics (Table I):
36/44 (81.8%) of T-Rapa6 pts had a diagnosis at highest risk
for disease progression (Kahl III) and/or were chemotherapy
refractory (stable or progressive disease to last regimen).
Similar to T-Rapa12 pts, mixed chimerism existed prior to T-
Rapa6 DLI (median T and myeloid chimerism at d14 post-
HCT: 44% and 35%, respectively). Similar to T-Rapa12 pts,
T-Rapa6 pts had a rapid increase in donor chimerism by d28
post-HCT with continued advancement towards full donor
chimerism by d100 post-HCT. Relative to T-Rapa12 pts, T-
Rapa6 pts had an increased frequency of acute GVHD at days
100 and 180 post-HCT; this increase was primarily attribut-
able to steroid-responsive gut disease. Chronic GVHD inci-
dence did not appear to be substantially increased in T-Rapa6
pts. T-Rapa6 and T-Rapa12 pts had similar survival probabil-
ities and frequency of sustained complete remission; in each
cohort, deaths were primarily due to progressive disease.
These data provide further support for evaluation of T-Rapa
cell pre-emptive DLI after low-intensity allogeneic HCT as
this approach associates with consistent alloengraftment,
sustained complete remissions, and low transplant-related
mortality. The differential gene expression proﬁle existent
between T-Rapa12 and T-Rapa6 cells is sufﬁcient to drive
differential acute GVHD effects.178
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Adoptive transfer of CMVpp65-speciﬁc T-cells(cCTL) from
CMV-seropositive(CMVpos) donors effectively restores anti-
viral-immunity after stem cell transplantation. However, the
naïve T-cells in cord blood(CB) and adult CMV-seronegati-
ve(CMVneg) donors require different culture systems togenerate cCTL. With a novel GMP-applicable protocol we
have reliably generated cCTL from CB and found that 15/15
CB T-cell lines recognized atypical epitopes of pp65. We then
expanded cCTL from CMVneg donors in a GMP-applicable
way by isolating naive T-cells and stimulating them with
pp65-Pepmix-pulsed antigen-presenting cells supple-
mented with IL2,IL7,IL12, and IL15. cCTL expanded from 8/11
CMVneg donors were primarily CD8+ T-cells(mean 71%).
cCTL secreted IFN-g in response to pp65-peptides(mean 224
spots) as measured in Elispot assays and lysed pp65-pulsed
target cells. cCTL derived from naive T-cells recognized only
novel and atypical pp65 epitopes (e.g. LQTGIHVR,MLNIP-
SINV) but not the typical epitope NLVPMVATV as conﬁrmed
by ELISPOT and Pentamer. Analysis of the avidity of naïve
donor CTL speciﬁc for the atypical CMV epitopes revealed
that the 1/2 -maximum effective concentration was similar
(mean:600pM) to CMVpos CTL recognizing typical epito-
pes(mean: 300pM), and more avid than CMVpos CTL
recognizing atypical epitopes(mean:4nM). TCR sequencing
performed on T-cells speciﬁc for typical(CMVpos) and aty-
pical(CMVpos,CMVneg, and CB) epitopes revealed that
CMVpos donor cCTL recognizing typical epitopes were
markedly less polyclonal. To address the concern that atyp-
ical epitopes might not be naturally presented by CMV-
infected cells and therefore not recognized by in vitro
generated CTL, we tested whether cCTL generated using CMV
AD169-infected ﬁbroblasts would recognize the same epi-
topes. CMVpos cCTL recognized typical epitopes while CB/
CMVneg cCTL recognized only atypical epitopes, suggesting
that the epitopes are naturally processed/presented by APCs.
Using deep TCR sequencing from the peripheral blood of CBT
recipients, the atypical epitope MLN was found in a similar
number of HLA-A2+ patients (6/9) than the typical epitope
(NLV) (5/9). These results reveal major, previously-unre-
ported differences in the naïve and memory CMV speciﬁc T-
cell repertoire but suggest that atypical epitopes may indeed
be important. Hence, we demonstrated that atypical epi-
topes are naturally presented by CMV-infected cells and are
now evaluating the clinical efﬁcacy of these CTL in recipients
of CBT.179
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Adoptive transfer of virus-speciﬁc T-cells (CTLs) from HLA
partially matched 3rdparty donors can effectively treat EBV,
CMV or Adv infections in recipients of HSCT from seroneg-
ative or cord blood donors. However, in vitro generated CTLs
selectively react against 1-3 immunodominant (ID) epitopes
(eps) presented by 1-2 HLA alleles. Therefore, to be effective,
it is critical that administered CTLs respond to eps presented
by HLA alleles shared by the recipient. To address this, we
established a bank of 123 GMP grade CMV-CTLs generated
using CMVpp65 peptide pool loaded autologous APCs. Each
